Advancement in Current Therapeutic Modalities in Postpartum Cardiomyopathy
- PMID: 35382200
- PMCID: PMC8976525
- DOI: 10.7759/cureus.22813
Advancement in Current Therapeutic Modalities in Postpartum Cardiomyopathy
Abstract
Pregnancy is considered one of the most delicate conditions for the woman and her fetus, rendering physiological stress on her body. Sometimes, this leads to unwelcomed incidences of certain systemic disorders which further complicate the course of pregnancy. Cardiovascular conditions associated with pregnancy have major morbidity amongst the general population. Peripartum cardiomyopathy, one such condition associated with cardiac dysfunction during pregnancy, is one of the major causes of increased morbidity and mortality in pregnant women. It has been the leading cause of non-obstetric maternal mortality. Due to the stress on the cardiovascular system, further functioning of the body in the milieu gets compromised and thus, the occurrence of fetomaternal mortality is not rare in the prognosis of this condition. Certain studies have noted not only familial but also geographical variations in the prevalence of peripartum cardiomyopathy in certain areas. Although the occurrence of the condition is quite common, there still needs to be a better understanding of this topic for avoiding the abysmal prognosis of this pathology. A peculiar presentation on the electrogram is needed to make an accurate diagnosis of the condition. The therapeutic options of this condition, particularly incline towards medical management. Various new drugs have been formulated and are in clinical trials for testing their effectiveness. Bromocriptine therapy, along with the neoadjuvant combination of anticoagulant drugs and non-pharmacological measures, makes a good treatment regimen that helps avert the progressive pathology. In this article, we discuss the knowledge regarding the etiology, factors contributing to the severity, pathogenesis, treatment options, and the particular outcomes of the therapy.
Keywords: bromocriptine; cardiac pathologies; feto maternal morbidity; peripartum cardiomyopathy; peripartum complications.
Copyright © 2022, Chaudhari et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Management of cardiac disease in pregnancy. Burt CC, Durbridge J. Contin Educat Anaesth Crit Care Pain. 2009;9:44–47.
-
- Peripartum cardiomyopathy: a review. Bhattacharyya A, Basra SS, Sen P, Kar B. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298938/ Tex Heart Inst J. 2012;39:8–16. - PMC - PubMed
-
- Peripartum cardiomyopathy - a case report and concise review [Article in Czech] Karafiatova L, Lazarova M, Taborsky M. Cor et Vasa. 2017;59:0.
-
- Incidence, mortality, and racial differences in peripartum cardiomyopathy. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, Shen AY. Am J Cardiol. 2007;100:302–304. - PubMed
-
- Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A. Circulation. 2005;111:2050–2055. - PubMed
Publication types
LinkOut - more resources
Full Text Sources